Building resilience into post-pandemic cell & gene therapy supply chains

Tiffany Clement, Cell Therapies Core Inventory Management & Support Services Manager, Moffitt Cancer Center & Cheryl Cox, Director of Operations of the Cell Therapies Facility, Moffitt Cancer Center

“There is a need in the industry for customers to know who they are ordering from, and to establish a purchasing partnership with manufacturers to ensure that raw materials of sufficient quality are reliably delivered.”

On October 19^th 2022, David McCall, Commissioning Editor of Cell & Gene Therapy Insights, spoke to Moffitt Cancer Center’s Tiffany Clement and Cheryl Cox about trends and issues in cell and gene therapy supply chain management. This article has been written based on that interview.

Please enter your email to access content Read now